Publication Name	World Journal of Diabetes
Manuscript ID	67845
Country	Greece

Received	2021-05-05 11:53
Peer-Review Started	2021-05-05 11:55
To Make the First Decision
Return for Revision	2021-06-16 14:39
Revised	2021-07-29 20:59
Second Decision	2022-01-25 03:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-01-26 22:26
Articles in Press	2022-01-26 22:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-01-27 08:02
Publish the Manuscript Online	2022-02-09 06:44

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
Manuscript Source	Invited Manuscript
All Author List	Matilda Florentin, Michael S Kostapanos and Athanasia K Papazafiropoulou
ORCID	Author(s) ORCID Number Matilda Florentin http://orcid.org/0000-0002-0135-9694 Michael S Kostapanos http://orcid.org/0000-0002-7513-5319 Athanasia K Papazafiropoulou http://orcid.org/0000-0002-7596-4942
Funding Agency and Grant Number
Corresponding Author	Athanasia K Papazafiropoulou, MD, MSc, PhD, Consultant Physician-Scientist, 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, Leoforos Afentouli, Athens 18536, Greece. athpapazafiropoulou@gmail.com
Key Words	Cardiovascular safety; Dipeptidyl peptidase 4 inhibitors; Glucose lowering; Hypoglycemia; Therapeutic algorithm; Weight gain
Core Tip	Dipeptidyl peptidase 4 inhibitors have a favorable safety profile, do not frequently cause hypoglycemia and weight gain, while they may be used in patients with kidney impairment and the elderly. Despite not reducing cardiovascular events, they still have a place in the diabetes treatment algorithm in several patients.
Publish Date	2022-02-09 06:44
Citation	Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes 2022; 13(2): 85-96
URL	https://www.wjgnet.com/1948-9358/full/v13/i2/85.htm
DOI	https://dx.doi.org/10.4239/wjd.v13.i2.85

Full Article (PDF)	WJD-13-85.pdf
Full Article (Word)	WJD-13-85.docx
Manuscript File	67845_Auto_Edited.docx
Answering Reviewers	67845-Answering reviewers.pdf
Audio Core Tip	67845-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	67845-Conflict-of-interest statement.pdf
Copyright License Agreement	67845-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	67845-Language certificate.pdf
Peer-review Report	67845-Peer-review(s).pdf
Scientific Misconduct Check	67845-Bing-Gao CC-2.png
Scientific Editor Work List	67845-Scientific editor work list.pdf